3 completed. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Cotoretigene Toliparvovec: new trials by email Literature Review of Cotoretigene Toliparvovec trials Research Report on Cotoretigene Toliparvovec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa BIIB111, BIIB112 - Choroideremia, X-Linked Retinitis Pigmentosa | Phase 3 | Completed | NightstaRx Ltd, a Biogen Company | 277 | 2018-06-04 | 2026-07-06 |
| Natural History of the Progression of X-Linked Retinitis Pigmentosa Other: Assessments - X-Linked Retinitis Pigmentosa | Completed | NightstaRx Ltd, a Biogen Company | 201 | 2017-09-13 | 2023-02-10 | |
| A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 BIIB112 - X-Linked Retinitis Pigmentosa | Phase 1 / Phase 2 | Completed | Biogen | 50 | 2017-03-08 | 2024-01-18 |
Choroideremia (1) · Cone-Rod Dystrophy, X-Linked, Type 1 (1) · Rare Diseases (1)
NightstaRx Ltd, a Biogen Company (2) · Biogen (1)
United Kingdom (3) · United States (3) · Canada (2) · Finland (2) · France (2) · Germany (2) · Netherlands (2) · Brazil (1) · Denmark (1)
PMID 36757689, PMID 32094925, PMID 38423215, PMID 40535564
2016 (1), 2017 (1)